Idaho Businesses Eligible for Generic Drug Settlement
Owners who purchased generic drugs between 2009 and 2019 may qualify for compensation under new antitrust settlement terms.
Updated on Oct. 21, 2026 in Healthcare
Live Poll
Do you believe legal settlements with large corporations provide fair compensation to affected consumers?
Idaho has joined a multistate settlement with several generic drug manufacturers to resolve allegations of price-fixing and suppressed competition. Eligible Idaho businesses that purchased specific prescription drugs between May 2009 and December 2019 may now pursue financial compensation.
Why it matters
The settlements address systemic antitrust concerns where manufacturers allegedly inflated costs and restrained trade for essential medications. This resolution forces industry-wide compliance reforms while providing a path for local operators to recoup historically overcharged expenses.
Idaho joined over 40 states and territories in securing payments from manufacturers, including $469 million from Sandoz and $1.05 million combined from Ascend Laboratories and Mayne Pharma. The settlements address price-fixing allegations involving generic prescription drugs.
The players
Sandoz Inc.
A major global manufacturer of generic and biosimilar pharmaceuticals.
Fougera Pharmaceuticals Inc.
A developer and manufacturer of prescription dermatological products.
Ascend Laboratories
A generic pharmaceutical company focused on the U.S. market.
Mayne Pharma
A specialty pharmaceutical company that focuses on commercializing generic and branded products.
The details
The manufacturers settled allegations that they artificially manipulated market prices and limited competition to the detriment of purchasers. Beyond financial restitution, the companies have committed to internal antitrust reforms and increased compliance oversight to prevent future market distortion. Idaho stands out as one of two states that successfully negotiated specific restitution provisions for businesses impacted by these practices.
Timeline
May 2009 to December 2019: Period of drug purchases eligible for compensation.
October 20, 2026: Announcement of the multistate settlements.
Market Landscape
The settlement marks a modern enforcement application of the Sherman Antitrust Act regarding competitive pricing, distinguishing it from standard consumer class actions. This follows a broader industry trend of state-led antitrust scrutiny targeting generic drug manufacturers for anti-competitive behaviors.
Idaho business owners should immediately verify if their historic pharmaceutical procurement records fall within the 2009–2019 window. Reviewing ledger data now is necessary to determine if an eligible claim can be filed through the state-sanctioned process.
The takeaway
This settlement provides a rare opportunity for businesses to recoup costs from over a decade of alleged market manipulation. Operators should document their historical purchase records and contact 1-866-290-0182 to confirm eligibility and filing requirements.
Further reading
For broader trends in industry regulation, see our coverage of Healthcare.
More information
Businesses can determine their eligibility for compensation via the generic drug settlement eligibility portal.
Live Poll
Do you believe legal settlements with large corporations provide fair compensation to affected consumers?
